|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/21 AIM ImmunoTech Inc. 10-K 12/31/20 94:7.6M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 797K
2: EX-4.23 Instrument Defining the Rights of Security Holders HTML 38K
3: EX-10.75 Material Contract HTML 174K
4: EX-10.76 Material Contract HTML 178K
5: EX-10.77 Material Contract HTML 73K
6: EX-10.78 Material Contract HTML 61K
7: EX-10.79 Material Contract HTML 28K
8: EX-10.80 Material Contract HTML 55K
9: EX-10.81 Material Contract HTML 57K
10: EX-21 Subsidiaries List HTML 25K
11: EX-23.1 Consent of Expert or Counsel HTML 24K
12: EX-23.2 Consent of Expert or Counsel HTML 27K
13: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
14: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
15: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
16: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
23: R1 Document and Entity Information HTML 61K
24: R2 Consolidated Balance Sheets HTML 112K
25: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
26: R4 Consolidated Statements of Comprehensive Loss HTML 86K
27: R5 Consolidated Statements of Changes in HTML 80K
Stockholders' Equity
28: R6 Consolidated Statements of Cash Flows HTML 126K
29: R7 Business HTML 36K
30: R8 Summary of Significant Accounting Policies HTML 53K
31: R9 Inventories HTML 29K
32: R10 Marketable Securities HTML 46K
33: R11 Patents, Trademark Rights, Net HTML 33K
34: R12 Accrued Expenses HTML 31K
35: R13 Stockholders' Equity HTML 125K
36: R14 Segment and Related Information HTML 32K
37: R15 Research, Consulting and Supply Agreements HTML 30K
38: R16 401(k) Plan HTML 29K
39: R17 Royalties, License and Employment Agreements HTML 34K
40: R18 Leases HTML 36K
41: R19 Income Taxes (FASB ASC 740 Income Taxes) HTML 40K
42: R20 Convertible Note Payable HTML 33K
43: R21 Note Payable HTML 32K
44: R22 Certain Relationships and Related Transactions HTML 29K
45: R23 Concentrations of Credit Risk HTML 28K
46: R24 Fair Value HTML 79K
47: R25 Financing Obligation Arising from Sale Leaseback HTML 36K
Transaction
48: R26 Subsequent Events HTML 31K
49: R27 Summary of Significant Accounting Policies HTML 85K
(Policies)
50: R28 Summary of Significant Accounting Policies HTML 31K
(Tables)
51: R29 Marketable Securities (Tables) HTML 45K
52: R30 Patents, Trademark Rights, Net (Tables) HTML 35K
53: R31 Accrued Expenses (Tables) HTML 30K
54: R32 Stockholders' Equity (Tables) HTML 115K
55: R33 Leases (Tables) HTML 30K
56: R34 Income Taxes (FASB ASC 740 Income Taxes) (Tables) HTML 34K
57: R35 Fair Value (Tables) HTML 70K
58: R36 Financing Obligation Arising from Sale Leaseback HTML 33K
Transaction (Tables)
59: R37 Business and Basis of Presentation (Details HTML 26K
Narrative)
60: R38 Summary of Significant Accounting Policies HTML 68K
(Details Narrative)
61: R39 Summary of Significant Accounting Policies - HTML 38K
Schedule of Property and Equipment (Details)
62: R40 Inventories (Details Narrative) HTML 29K
63: R41 Marketable Securities (Details Narrative) HTML 28K
64: R42 Marketable Securities - Schedule of Available for HTML 57K
Sale (Details)
65: R43 Patents, Trademark Rights, Net (Details Narrative) HTML 26K
66: R44 Patents,Trademark Rights, Net - Schedule of HTML 35K
Patents, Trademark Rights, Net (Details)
67: R45 Patents, Trademark Rights, Net - Schedule of HTML 41K
Amortization of Patents and Trademarks (Details)
68: R46 Accrued Expenses - Schedule of Accrued Expenses HTML 37K
(Details)
69: R47 Stockholders' Equity (Details Narrative) HTML 258K
70: R48 Stockholders' Equity - Schedule of Options and HTML 40K
Equity Estimated Based on Weighted Average
Assumptions (Details)
71: R49 Stockholders' Equity - Schedule of Stock Option HTML 134K
Activity (Details)
72: R50 Stockholders' Equity - Schedule of Unvested Stock HTML 70K
Option Activity (Details)
73: R51 Stockholders' Equity - Schedule of Warrants HTML 67K
Outstanding and Exercisable (Details)
74: R52 Research, Consulting and Supply Agreements HTML 27K
(Details Narrative)
75: R53 401(k) Plan (Details Narrative) HTML 35K
76: R54 Royalties, License and Employment Agreements HTML 75K
(Details Narrative)
77: R55 Leases (Details Narrative) HTML 65K
78: R56 Leases - Schedule of Operating lease Future HTML 40K
Payments (Details)
79: R57 Income Taxes (FASB ASC 740 Income Taxes) (Details HTML 40K
Narrative)
80: R58 Income Taxes (FASB ASC 740 Income Taxes) - HTML 45K
Schedule of Components of Net Deferred Tax Assets
and Liabilities (Details)
81: R59 Convertible Note Payable (Details Narrative) HTML 77K
82: R60 Note Payable (Details Narrative) HTML 65K
83: R61 Certain Relationships and Related Transactions HTML 29K
(Details Narrative)
84: R62 Fair Value (Details Narrative) HTML 32K
85: R63 Fair Value - Schedule of Assumptions to Estimate HTML 75K
Fair Value of Warrants (Details)
86: R64 Fair Value - Schedule of Range of Probabilities HTML 29K
(Details)
87: R65 Fair Value - Schedule of Assets and Liabilities HTML 34K
Measured at Fair Value on a Recurring Basis
(Details)
88: R66 Fair Value - Schedule of Changes in Level 3 HTML 29K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
89: R67 Financing Obligation Arising from Sale Leaseback HTML 43K
Transaction (Details Narrative)
90: R68 Financing Obligation Arising from Sale Leaseback HTML 55K
Transaction - Schedule of Future Minimum Payments
Under Financing Obligation (Details)
91: R69 Subsequent Events (Details Narrative) HTML 42K
93: XML IDEA XML File -- Filing Summary XML 154K
92: EXCEL IDEA Workbook of Financial Reports XLSX 112K
17: EX-101.INS XBRL Instance -- aim-20201231 XML 1.86M
19: EX-101.CAL XBRL Calculations -- aim-20201231_cal XML 211K
20: EX-101.DEF XBRL Definitions -- aim-20201231_def XML 757K
21: EX-101.LAB XBRL Labels -- aim-20201231_lab XML 1.42M
22: EX-101.PRE XBRL Presentations -- aim-20201231_pre XML 966K
18: EX-101.SCH XBRL Schema -- aim-20201231 XSD 259K
94: ZIP XBRL Zipped Folder -- 0001493152-21-007259-xbrl Zip 174K
Exhibit 10.79
FIRST AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENT
This First Amendment to the Manufacture and Supply Agreement (the “First Amendment”) is made effective as of December 23, 2020 (the “Effective Date”), by and between Pharmaceutics International, Inc. (“PII”) and AIM Immuno Tech Inc. (“Customer”).
EXPLANATORY STATEMENT
PII and Customer entered into a Manufacture and Supply Agreement dated as of December, December 22, 2020 (the “Agreement”). The parties have agreed to amend the terms of the Agreement upon the terms and conditions set forth herein. Capitalized terms not otherwise defined herein shall be as defined in the Agreement.
NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and in the Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
The following language shall be added to Section 16 Miscellaneous.
“16.12 Customer is a public company therefore, any agreements in Customer’s judgement, that are required to be publicly disclosed as a material event under Federal and state securities laws, rules and regulations, including events that AIM has customarily disclosed in the past, including this agreement, will be considered material and as such reports will be filed in AIMs 8K, 10K and 10Qs that address Customer’s contractual relationships.”
Except as modified by the terms of this First Amendment, the Agreement shall continue to be in full force and effect and, by their signatures below, the parties hereto agree to be bound by all of the terms and conditions of the Agreement, as amended hereby.
IN WITNESS WHEREOF, the parties hereto have executed this First Amendment under seal as of the Effective Date.
| AIM IMMUNOTECH INC. | PHARMACEUTICS INTERNATIONAL, INC. | |||
| By: | /s/ Peter W. Rodino, III, J.D. | By: | /s/ John Guthrie | |
| Name: | Peter W. Rodino, III, J.D. | Name: | John Guthrie | |
| Title: | Chief Operating Officer | Title: | CFO | |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/31/21 | 10-Q | ||
| Filed on: | 3/30/21 | |||
| For Period end: | 12/31/20 | |||
| 12/23/20 | 8-K | |||
| 12/22/20 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 4/19/23 AIM ImmunoTech Inc. 424B5 1:431K M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 5/13/22 AIM ImmunoTech Inc. 10-Q 3/31/22 68:5.6M M2 Compliance LLC/FA 3/31/22 AIM ImmunoTech Inc. 10-K 12/31/21 90:9.3M M2 Compliance LLC/FA 1/21/22 AIM ImmunoTech Inc. S-3 5:822K M2 Compliance LLC/FA 7/01/21 AIM ImmunoTech Inc. S-8 7/01/21 4:140K M2 Compliance LLC/FA 5/17/21 AIM ImmunoTech Inc. 10-Q 3/31/21 73:4.7M M2 Compliance LLC/FA |